

News Releases

All Years

Search

Go

[Advanced Search](#)

DEC 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

NOV 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NOV 3, 2021

Inhibrx Announces Presentations at SITC 2021

NOV 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

OCT 28, 2021

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

SEP 13, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

AUG 9, 2021

Inhibrx Reports Second Quarter 2021 Financial Results

Inhibrx Reports Second Quarter 2021 Financial Results

JUN 21, 2021

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford

MAY 17, 2021

Inhibrx Announces Participation in Upcoming Investor Conferences

MAY 13, 2021

Inhibrx Reports First Quarter 2021 Financial Results

MAR 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

NOV 10, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 21, 2019

Inhibrx Announces \$40M Investment from Viking Global Investors

FEB 19, 2019

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

JAN 7, 2019

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

DEC 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

Show per
page

«	1	2	3	4	»
-------------------	-------------------	-------------------	---	-------------------	-------------------



<https://inhibrxbiosciences.investorroom.com/news-releases?l=25&o=50>